IVIG Shows Benefit in Inflammatory Myopathy, but Thromboembolic Risks Noted
In a randomized trial, patients with newly diagnosed idiopathic inflammatory myopathies who received IVIG plus prednisone showed greater improvement in disease activity scores than those on prednisone alone. The mean Total Improvement Score increased by 60 points with IVIG versus 42.5 with placebo. However, a deep vein thrombosis and a death highlighted potential thromboembolic risks, prompting consideration of prophylactic anticoagulation.
The Dutch trial enrolled 42 adults with newly diagnosed idiopathic inflammatory myopathies, evenly split between sexes, with symptoms averaging nearly six months before diagnosis. IVIG was infused at 2 g/kg at weeks 0, 4, and 8 alongside a tapering prednisone regimen, while controls received saline. Beyond the primary Total Improvement Score, secondary efficacy measures also favored the IVIG group. However, one patient developed deep vein thrombosis and another died from unknown causes, underscoring safety concerns that have long shadowed immunoglobulin therapy. The authors suggested prophylactic anticoagulation may be warranted when IVIG is used in this population, though no formal recommendation was made.
This trial could reshape initial treatment protocols for inflammatory myopathies, offering clinicians a rigorously tested option beyond corticosteroids alone. Patients may benefit from faster, more substantial disease control, potentially reducing long-term muscle damage and disability. However, the thromboembolic events raise caution, meaning physicians may need to weigh anticoagulation strategies carefully. Broader adoption could also affect healthcare costs, given IVIG's expense and infusion requirements, potentially influencing insurance coverage decisions and treatment accessibility for newly diagnosed patients.